title: Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
abstract: c-Met plays an important role in colorectal tumorigenesis and disease progression and thus is believed to be an attractive inhibitory target for receptor molecular therapeutic. SU11274 was identified as a small molecule, ATP competitive inhibitor of the catalytic activity of the c-Met kinase. Our study had investigated the relationship between the high expression of c-Met and colorectal carcinoma and the effect of c-Met inhibitor SU11274 in colorectal carcinoma in vitro and vivo. Immunohistochemistry was used to detect the expression of c-Met in 60 patients with colorectal cancer and 20 patients with benign adenoma and surrounding normal colon tissues. The effect of SU11274 on human colorectal carcinoma LoVo cells was detected by Western blot and MTT. And the influence of SU11274 on cell cycle was determined by flow cytometry. In addition, LoVo cell-transplanted tumor growth and expression of c-Met in nude mice was examined for inhibition of SU11274 in vivo. We found c-Met had high expression and was closely related to lymph node metastasis and TNM stage in colorectal carcinoma tissues. SU11274 significantly suppressed the phosphorylation of c-Met as well as the survival and proliferation of LoVo cell lines. G1-phase arrest was also induced by SU11274. SU11274 apparently restrained the growth of the xenograft tumor in nude mice. Our data suggest developing therapies that specifically inhibit the activation of c-Met may represent a novel therapeutic modality for patients with colorectal carcinoma expressing high levels of c-Met.
authors.affiliation: Department of Oncology, Central Hospital of Jinan, Jiefang Road 105, Jinan 250013, People's Republic of China. gjygw-1994@163.com
authors.forename: Wei
authors.initials: W
authors.lastname: Gao
authors.forename: Xue
authors.initials: X
authors.lastname: Bing
authors.forename: MingYan
authors.initials: M
authors.lastname: Li
authors.forename: Zhanhua
authors.initials: Z
authors.lastname: Yang
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.forename: Hua
authors.initials: H
authors.lastname: Chen
mesh_terms: D000236:Adenoma / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000556:secondary; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays / Q000379:methods
chemical_list: C478479:((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide); D007211:Indoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; C080835:RON protein; D020794:Receptor Protein-Tyrosine Kinases
references.citation: J Natl Cancer Inst. 2011 Apr 20;103(8):645-61
references.pmid: 21464397
references.citation: Int J Cancer. 2000 May 20;89(3):286-92
references.pmid: 10861506
references.citation: Anticancer Res. 1997 May-Jun;17(3C):2241-7
references.pmid: 9216695
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21
references.pmid: 16461907
references.citation: Anticancer Res. 2001 Nov-Dec;21(6B):4243-52
references.pmid: 11908677
references.citation: Nat Rev Cancer. 2012 Jan 24;12(2):89-103
references.pmid: 22270953
references.citation: Cancer Res. 2003 Nov 1;63(21):7345-55
references.pmid: 14612533
references.citation: Clin Cancer Res. 2004 Oct 1;10(19):6686-94
references.pmid: 15475459
references.citation: Neoplasia. 2006 Nov;8(11):949-55
references.pmid: 17132227
references.citation: Curr Drug Targets. 2001 Mar;2(1):41-55
references.pmid: 11465538
references.citation: Oncogene. 2003 Nov 20;22(52):8498-508
references.pmid: 14627990
references.citation: Cancer Res. 2003 Nov 15;63(22):7926-35
references.pmid: 14633723
references.citation: Cancer Metastasis Rev. 2003 Dec;22(4):309-25
references.pmid: 12884908
references.citation: Crit Rev Oncol Hematol. 1999 Feb;29(3):209-48
references.pmid: 10226727
references.citation: Acta Med Okayama. 1998 Dec;52(6):305-10
references.pmid: 9876767
references.citation: Cancer Res. 2007 Apr 15;67(8):3529-34
references.pmid: 17440059
references.citation: J Cell Physiol. 2001 Dec;189(3):285-90
references.pmid: 11748586
references.citation: Cancer Res. 2003 Sep 1;63(17):5462-9
references.pmid: 14500382
references.citation: Virchows Arch. 2002 Apr;440(4):362-6
references.pmid: 11956815
references.citation: Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):202-11
references.pmid: 14734471
references.citation: Clin Cancer Res. 2001 Nov;7(11):3519-25
references.pmid: 11705871
references.citation: Oncogene. 1996 Aug 15;13(4):853-6
references.pmid: 8761307
references.citation: Cancer Res. 2003 Oct 1;63(19):6272-81
references.pmid: 14559814
references.citation: Leuk Res. 2004 May;28 Suppl 1:S29-38
references.pmid: 15036939
references.citation: Head Neck. 2008 Aug;30(8):991-1000
references.pmid: 18327775
references.citation: Oncogene. 1994 Apr;9(4):1091-9
references.pmid: 8134112
references.citation: Cancer Lett. 2005 Jul 8;225(1):1-26
references.pmid: 15922853
references.citation: Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6
references.pmid: 9012848